Current Oncology | Top Cited Papers in 2022 in the Section “Medical Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Medical Oncology” below:
1. “Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria”
by Philippe d’Abadie, Stephan Walrand, Renaud Lhommel, Michel Hesse, Ivan Borbath and François Jamar
Curr. Oncol. 2022, 29(4), 2422-2434; https://doi.org/10.3390/curroncol29040196
Available online: https://www.mdpi.com/1718-7729/29/4/196
2. “Health Literacy and Clinical Trial Participation in French Cancer Patients: A National Survey”
by Youssoufa M. Ousseine, Anne-Déborah Bouhnik and Julien Mancini
Curr. Oncol. 2022, 29(5), 3118-3129; https://doi.org/10.3390/curroncol29050253
Available online: https://www.mdpi.com/1718-7729/29/5/253
3. “5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice”
by Takuo Yamai, Kenji Ikezawa, Yasuharu Kawamoto, Takeru Hirao, Sena Higashi, Kazuma Daiku, Shingo Maeda, Yutaro Abe, Makiko Urabe, Yugo Kai et al.
Curr. Oncol. 2022, 29(4), 2644-2649; https://doi.org/10.3390/curroncol29040216
Available online: https://www.mdpi.com/1718-7729/29/4/216
4. “Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma”
by Randeep Sangha, Neal M. Davies, Afshin Namdar, Michael Chu, Jennifer Spratlin, Erwan Beauchamp, Luc G. Berthiaume and John R. Mackey
Curr. Oncol. 2022, 29(3), 1939-1946; https://doi.org/10.3390/curroncol29030158
Available online: https://www.mdpi.com/1718-7729/29/3/158
5. “Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events”
by Arezou Teimouri, Laura V. Minard, Samantha N. Scott, Amanda Daniels and Stephanie Snow
Curr. Oncol. 2022, 29(5), 3104-3117; https://doi.org/10.3390/curroncol29050252
Available online: https://www.mdpi.com/1718-7729/29/5/252
6. “Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline”
by Phillip Blanchette, Duvaraga Sivajohanathan, John Bartlett, Andrea Eisen, Harriet Feilotter, Rossanna Pezo, Gulisa Turashvili and Phillip Williams
Curr. Oncol. 2022, 29(4), 2599-2615; https://doi.org/10.3390/curroncol29040213
Available online: https://www.mdpi.com/1718-7729/29/4/213
7. “Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study”
by Alexandra Moskalewic, Amy Di Tomaso, Jacob J. Kachura, Samantha Scime, Rosane Nisenbaum, Ronita Lee, Rashida Haq, Christine Derzko and Christine Brezden-Masley
Curr. Oncol. 2022, 29(3), 1813-1827; https://doi.org/10.3390/curroncol29030149
Available online: https://www.mdpi.com/1718-7729/29/3/149
8. “The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study”
by Covadonga Martí, Laura Yébenes, José María Oliver, Elisa Moreno, Laura Frías, Alberto Berjón, Adolfo Loayza, Marcos Meléndez, María José Roca, Vicenta Córdoba et al.
Curr. Oncol. 2022, 29(4), 2199-2210; https://doi.org/10.3390/curroncol29040179
Available online: https://www.mdpi.com/1718-7729/29/4/179
9. “Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists”
by Irena Druce, Karine Tawagi, Julie L. V. Shaw, Andrea Ibrahim, Heather Lochnan and Michael Ong
Curr. Oncol. 2022, 29(7), 4665-4677; https://doi.org/10.3390/curroncol29070370
Available online: https://www.mdpi.com/1718-7729/29/7/370